To evaluate the impact of preoperative risk category on metastatic disease and prostate cancer-specific mortality (CSM) in patients with prostate cancer (PCa) with adverse pathology at radical prostatectomy (RP).
Introduction
Patients with prostate cancer (PCa) represent a heterogeneous group. Some will experience metastatic progression and die from PCa, while others will live with their disease and die from something else. Awareness of these differences among urologists has led to an increase in individualized treatment [1] . Physicians strive to select patients who are at low risk of progression and death for active surveillance strategies, however, up to 30% of patients with preoperatively low-risk status present adverse pathological features at radical prostatectomy (RP) [2, 3] . Active surveillance protocols have often been rated according to upgrading and upstaging rates [4] . Upgrading and upstaging rates have also been used as quality criteria for MRI-targeted detection and for MRIguided active surveillance [5] [6] [7] . Furthermore, patients with unfavourable pathological features at RP are likely to receive adjuvant treatment based on the hypothesis that unfavourable pathological outcomes are associated with higher rates of progression and death.
Imnadze et al. [8] showed that patients in the low-risk group with adverse pathological features do not have the same detrimental biochemical recurrence (BCR) rates as patients in preoperative intermediate-or high-risk groups; however, it remains unclear from that study if this translates into lower rates of metastatic disease and cancer-specific mortality (CSM). In addition, their study population was from North America, where screening behaviour and stage distribution may differ from those in European populations [9] and the findings from their study require validation.
The aim of the present study was to evaluate the impact of preoperative risk on metastatic progression and CSM. Additionally, we tested if the lower BCR rate in low-risk patients with unfavourable pathological outcomes was applicable to a European cohort of patients.
Patients and Methods

Study Population and Intervention
Using our institutional Martini-Klinik database, 6 943 patients treated with RP at our high-volume institution between 1992 and 2008 were identified and included in the present study. Patients with missing data on clinical biopsy and pathology variables (PSA, n = 45; clinical stage, n = 374; Gleason score at biopsy, n = 386; pathological stage, n = 18; and grade, n = 26) were excluded. Additionally, patients treated with neoadjuvant or adjuvant androgen deprivation therapy (n = 256) were excluded.
In our study cohort, RP was performed using an open retropubic approach by staff urologists, as described previously [10] [11] [12] [13] . All patients were diagnosed by multicore TRUS-guided biopsy. Biopsy cores were graded according to the Gleason system [14] , and clinical stage was assigned by the attending urologist according to the 1992-2002 American Joint Committee on Cancer TNM guidelines.
The pathological specimen was processed using serial step segmentation at 3-mm intervals according to the Stanford protocol [15] . Tumours were graded according to the Gleason system [14] . Pathological staging was assigned using the 2002 TNM system [16] . Patients with surgery prior to 2002 were restaged. Annual questionnaires and death reports from the National Cancer Registry were used for follow-up. The attending urologists conducted follow-up. Adherence to PCa guidelines is 93% among German urologists [17] . All data were prospectively stored in an institutional database (FILEMAKER pro 10; FileMaker Inc., Santa Clara, CA, USA).
Risk Stratification
Patients were stratified, according to the D'Amico risk stratification system, into low-, intermediate-and high-risk groups [18] . The D'Amico risk groups rely on three variables: PSA levels, which were categorized into ≤10, 10.1-20 and ≥20 ng/mL; clinical stage, defined as cT1/2a, cT2b and ≥cT2c/T3; and biopsy Gleason score, defined as ≤6, 7 and ≥8.
Statistical Analyses
In the first part of the analyses, BCR, metastatic progression and CSM rates were evaluated for patients with adverse pathological outcomes (Table 2) . Specifically, Kaplan-Meier analyses with the endpoint BCR and metastatic disease at 10 years were performed, and results were computed for patients with: (i) extracapsular extension (ECE); (ii) seminal vesicle invasion (SVI); (iii) pathological Gleason score ≥3+4; (iv) pathological Gleason score ≥4+3; (v) lymph node invasion (LNI); and (vi) positive surgical margins (PSMs). Upgrading was defined as higher Gleason score at final pathology than at biopsy. Upstaging was defined as ECE, SVI, LNI or PSMs in patients with preoperative low-risk status. All Kaplan-Meier analyses were stratified according to preoperative risk categories (D'Amico low-risk vs intermediate-and high-risk categories). Cumulative incidence smoothed plots were used to estimate 10-year CSM and other-cause mortality for the above-mentioned subgroups.
In the second part of the analyses, regression models were used to examine the association between D'Amico risk group and oncological outcomes (Table 3) . Specifically, uni-and multivariate Cox regression models were fitted to examine the association between D'Amico risk group and BCR for patients with unfavourable pathological outcomes: six regression models were fitted for patients with: (i) ECE; (ii) SVI; (iii) pathological Gleason score ≥3+4; (iv) pathological Gleason score ≥4+3; (v) LNI; and (vi) PSMs. All models were adjusted for age at surgery, year of surgery and the remaining unfavourable pathological outcomes. For example, risk of BCR among patients with ECE was tested for D'Amico lowrisk patients vs D'Amico intermediate-and high-risk patients, adjusted for the above-mentioned variables except ECE. All analyses were repeated with the endpoint metastatic disease. To analyse the third oncological outcome (CSM), we used competing risk regression models, which test the effect of D'Amico risk group on CSM after adjusting for other-cause mortality [19] . Once more, models were fitted for all six subgroups of patients.
To assess potential changes in pathology reports and surgical technique, we performed sub-analyses in a more contemporary cohort (surgery after 2004). In addition, subgroup analyses were performed to test for stability regardless of low-grade definition. We repeated our multivariable regression analyses within the subgroup (A) using the CAPRA low-risk definition, including percentage of tumour involvement at biopsy [20] , and within the subgroup (B) using the D'Amico low-risk definition criteria plus ≤2 cores affected.
All tests were two-tailed, and P values <0.05 were taken to indicate statistical significance. Statistical analyses were performed using R Version 3.1.0 (R Project for Statistical Computing, www.R-project.org).
Results
Patient Characteristics
Patient characteristics stratified according to D'Amico risk groups are shown in Table 1 The overall upgrading rate was 41.3%, and 1 237 low-risk patients (39.0%) were upgraded. For low-risk patients, the upgrading rate to Gleason score 3+4 was 36.0%, and to Gleason score ≥4+3 it was 3.0%. For intermediate-risk patients the upgrading rate to Gleason score ≥4+4 was 2.3%.
Overall, 729 low-risk patients (22.4%) were upstaged. A total of 345 (10.6%), 83 (2.5%), 11 (0.3%) and 443 patients (13.6%) in the low-risk group were diagnosed with ECE, SVI, LNI and/or PSM, respectively, at RP.
Kaplan-Meier and Cumulative Incidence Analyses
The median follow-up time among survivors was 96 months. BCR, metastasis and CSM rates for patients with unfavourable pathological outcomes at 10 years are listed in Table 2 . Among patients with ECE, the 10-year BCR rate was 26% vs 50% for low vs intermediate/high-risk patients (P < 0.001), while the 10-year metastasis rate was 1.6% vs 8%, respectively (P < 0.001). The estimated 10-year CSM rate was 2% vs 5% (P = 0.041) for low vs intermediate/high-risk patients, respectively.
Among patients with Gleason score ≥3+4 at final histopathology, the 10-year BCR rate was 25% (CI 22-28) vs 48% (CI 46-50) for low-vs intermediate-/high-risk patients (P < 0.001). The 10-year metastasis rate was 3.0% vs 12% for low-vs intermediate-/high-risk patients (P < 0.001), while 10-year CSM rate was 3% vs 8%, respectively (P < 0.001).
Among patients with histopathological Gleason score ≥4+3, the 10-year BCR rate was 56% (CI 42-66) vs 68% (CI 64-71; P < 0.001), the 10-year metastasis rate was 11% vs 24% (P < 0.001) and the 10-year CSM rate was 6% vs 17% for low-vs intermediate-/high-risk patients (P = 0.06).
Among patients with PSMs, the 10-year BCR rate was 32% (CI 27-67) vs 66% (CI 59-67) (P < 0.001), the 10-year metastasis rate was 2.9% vs 15% (P < 0.001) and the 10-year CSM rate was 4% vs 10%, for low-vs intermediate-/high-risk patients (P < 0.001). Among patients with positive lymph nodes or SVI, the 10-year BCR, metastasis and CSM rates were not significantly different between low-and intermediate-/high-risk patients (Table 2) .
Multivariable Analyses
To assess the risk of BCR, multivariable Cox regression analyses were used ( 
Subgroup Analyses
To assess potential changes in pathology reports and surgical technique, we performed sub-analyses in a more contemporary cohort (surgery after 2004). Upgrading and upstaging rates in preoperative low-risk patients in terms of LNI were 0.5% vs 0.3% (P = 0.09) for the more contemporary cohort vs the overall cohort. No significant difference was reported for SVI (1.9% vs 2.5%; P = 0.2) or ECE (10.4% vs 10.6%; P = 0.9). The PSM rate was lower in the more contemporary cohort (11.3% vs 13.6%; P = 0.019), but the Gleason score upgrading rate was higher in the more contemporary cohort (upgrading to Gleason score 3+4: 41.9% vs 36%, upgrading to Gleason score ≥4+3: 3.9 vs 3.0%; all P < 0.001).
Subgroup analyses were performed to test for stability regardless of low-grade definition. We repeated our multivariable regression analyses within the subgroup (A) in which the CAPRA low-risk definition, including percentage of tumour involvement at biopsy, was used [20] , and within the subgroup (B) in which the D'Amico low-risk definition criteria plus ≤2 cores affected were used.
Complete data on tumour involvement were available in 4 262 patients (subgroup A). Complete data on number of positive cores were available 4 637 patients (subgroup B). Results of the multivariable regression analyses were virtually unchanged for both subgroups. For subgroup A, in patients with pathological Gleason score ≥4+3 and PSMs, a statistically significant association between metastatic disease and D'Amico risk status was not achieved because of the low number of events (metastases). Using the low-risk definition in subgroup B (D'Amico criteria plus ≤2 cores affected) resulted in a lower risk of BCR, metastases and CSM in patients with Gleason score upgrading and preoperative low-risk disease. The HRs were similar to those for the plain D'Amico definition. In patients with SVI and LNI the number of events was too small in our subgroups to achieve meaningful results.
Discussion
It is known that unfavourable pathological outcome is associated with a higher risk of recurrence and death [21, 22] . This is probably why urologists conclude that low-risk patients with upgrading and upstaging have the same detrimental oncological outcomes as patients with preoperative intermediate-or high-risk PCa. Nonetheless, it is unclear if this thesis is correct. Despite this, recommendation for adjuvant treatment is mainly based on pathological outcome, without taking into account the preoperative risk category [23] . In addition, most studies on multiparametric MRI use pathological outcome, e.g. upgrading and upstaging, as the 'gold standard' [6, 7] . According to the present results, unfavourable pathological outcome might not be a sufficient endpoint for planning adjuvant treatment, and pathological outcome alone might not correctly show the risk of progression and death for low risk patients.
Imnadze et al. [8] reported lower BCR rates in patients with preoperative low-risk status than in their counterparts with ECE, extracapsular extension; LNI, lymph node invasion; PSM, positive surgical margin; SVI, seminal vesicle invasion. Kaplan-Meier analyses were used for biochemical recurrence and metastasis; cumulative incidence estimates were used for cancer-specific mortality.
© 2017 The Authors BJU International © 2017 BJU International 669 preoperatively intermediate-and high-risk status. Nonetheless, BCR might not reduce quality of life and cancer-specific life expectancy in a large group of affected patients. Our results partly confirm the findings of Imnadze et al. Similarly to their study, most upgrading in the present study was from Gleason 3+3 to Gleason 3+4 (87.1% vs 86%). Overall upgrading rates were higher in the present cohort (30% vs 41%). Notably, a significant proportion of the prostate biopsies were not performed at our institution; however, upgrading and upstaging rates are consistent with previous reports [24, 25] .
Patients with a preoperatively low-risk disease status who are diagnosed with ECE, positive lymph nodes or Gleason >3+4 do not have the same detrimental biochemical outcome as men with preoperatively intermediate-or high-risk disease (HRs 0.61, 0.62 and 0.70, respectively). In addition, when the endpoint was development of metastasis, low-risk status emerged as a protective factor among men with ECE, Gleason score ≥3+4 and ≥4+3, as well as PSMs (HRs 0.47, 0.51, 0.41 and 0.46, respectively). Nonetheless, in multivariable competing risk regression analyses with the endpoint CSM, low-risk status was not a significant risk-reducing factor, except for patients with upgrading to Gleason 3+4. It is likely that the low incidence of CSM is the main reason that statistical significance is not achieved.
A possible explanation for the improved outcome in low-risk patients with unfavourable Gleason scores is that they might have a lower proportion of Gleason pattern 4 disease. The proportion of Gleason 4 disease, more than its absence or presence, might be the predominant factor for progression of PCa. This hypothesis is consistent with previous results [26] . The same argument might be true for the effect of preoperative risk status on BCR in patients with ECE or positive lymph nodes. Patients with preoperatively low-risk PCa might have a lower extent of ECE and LNI than those with high-risk PCa.
Our results are of importance for counselling low-risk patients who encounter upstaging or upgrading at RP. They should be informed that they still do not have the same adverse clinical outcome as those with preoperative intermediate-/high-risk PCa with unfavourable pathological results. In addition, our results are helpful for the interpretation of detection studies and imaging trials that use pathological results as the 'gold standard'.
The present study has several strengths. First, we included a large patient cohort, with an extended follow-up of 96 months among survivors. Second, because of this long follow-up we were able to report on strong endpoints, such as development of metastasis and CSM rates, in addition to BCR. Third, we used data from a European cohort. Taking into account the results of Imnadze et al. [8] , the present study could be considered a validation study in a patient population with distinct PSA testing and PCa detection protocols. Finally, our results were robust to several low-risk definitions. Limitations of the present study include the fact that the data originate from a large single centre and might not be applicable to smaller hospitals. Additionally, differences between low-risk and intermediate-/high-risk patients might be biased by unmeasured confounders such as overall tumour volume, proportion of Gleason pattern 4 disease, length and Gleason pattern of the PSMs, as well as amount of LNI; however, some of these variables are not reported in standard pathological records, and preoperative risk category might serve as a surrogate variable.
Another limitation is the potential impact of time-dependent changes in surgical and pathological techniques; however, subanalyses in a cohort treated after 2005 showed no clinically significant changes in upgrading or upstaging rates.
Lastly, metastatic disease might be underestimated in patients with low-risk status. To test the effect of a higher rate of metastasis, we performed additional sensitivity analyses. For this purpose we assumed a 100% higher rate of metastasis in patients with low-risk status and repeated the analyses with this assumed metastasis rate. The results were virtually the same (data not shown).
In conclusion, patients with preoperatively low-risk status have a statistically and clinically significantly lower risk of metastatic disease and CSM than their intermediate-/high-risk counterparts when adverse pathological features are identified at RP. This should be emphasized in patient counselling after RP. These results should also be taken into account when interpreting results from active surveillance and PCa imaging trials.
